Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...
Hosted on MSN
6 types of treatment for complement 3 glomerulopathy
Managing complement 3 glomerulopathy involves several treatment options aimed at slowing disease progression and protecting kidney function. These may include blood pressure control, steroids, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling ...
MarketBeat on MSN
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company ...
Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results